TABLE 1.
Liver function tests in patients infected with hepatitis C virus (n = 6982) at baseline and during and after DAA therapy, from the German Hepatitis C Registry
| ALT (U/L) | GGT (U/L) | |||
|---|---|---|---|---|
| Mean ± SD | Median (IQR) | Mean ± SD | Median (IQR) | |
| Baseline, n = 6982 | 87 ± 76 | 64 (41–104) | 102 ± 135 | 63 (34–120) |
| DAA therapy week 4, n = 5821 | 30 ± 26 | 24 (17–34) | 49 ± 62 | 33 (22–56) |
| DAA therapy week 8, n = 4311 | 30 ± 23 | 23 (17–34) | 45 ± 65 | 29 (20–46) |
| End‐of‐treatment, n = 6238 | 28 ± 24 | 22 (16–31) | 38 ± 57 | 24 (17–40) |
| Follow‐up week 12, n = 5381 | 26 ± 25 | 21 (16–29) | 40 ± 64 | 24 (17–41) |
| Follow‐up week 24, n = 6982 | 27 ± 28 | 20 (15–29) | 42 ± 74 | 24 (16–40) |
| Follow‐up 1 year, n = 3401 | 27 ± 92 | 21 (16–29) | 44 ± 73 | 25 (17–43) |
| Follow‐up 2 years, n = 2552 | 26 ± 22 | 21 (15–29) | 42 ± 71 | 25 (17–43) |
| Follow‐up 3 years, n = 1651 | 25 ± 17 | 21 (16–29) | 41 ± 68 | 25 (17–40) |
| Follow‐up 4 years, n = 1281 | 25 ± 15 | 21 (17–29) | 39 ± 46 | 25 (17–41) |
| Follow‐up 5 years, n = 721 | 28 ± 31 | 22 (17–30) | 42 ± 60 | 25 (17–42) |
Abbreviations: ALT, alanine aminotransferase; DAA, direct acting antivirals; GGT, gamma‐glutamyltransferase; IQR, interquartile range.